Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years. - Akin C; Sabato V; Gotlib J; Panse J; Álvarez-Twose I; Radia DH; Livideanu CB; Jurcic J; Elberink HO; Van Daele P; Cerquozzi S; Dybedal I; et al. (The Journal of allergy and clinical immunology, 2026)